Relay Therapeutics Rides Analyst Wave to 15% Surge

Now, when Guggenheim Securities’ Brad Canino rode into town Wednesday after market hours, he didn’t just hang his hat on Relay’s porch-he declared it a “Buy” with a $15 price target that stretches nearly four times the current share price. That’s the sort of optimism that makes even the weariest investor perk up like a hound dog catching a whiff of fresh game. The analyst dubbed it his firm’s “Best Idea,” which is Wall Street’s way of saying “bet your bottom dollar, but keep your boots by the door.”








